AIM ImmunoTech (AIM) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		51,281,437

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,295,000	$ 5,439,000
Marketable investments	7,647,000	7,631,000
Funds receivable from New Jersey net operating loss and Other Receivables		1,184,000
Prepaid expenses and other current assets	364,000	302,000
Total current assets	11,306,000	14,556,000
Property and equipment, net	118,000	127,000
Right of use asset, net	763,000	697,000
Patent and trademark rights, net	2,314,000	2,313,000
Other assets	1,688,000	1,688,000
Total assets	16,189,000	19,381,000
Current liabilities:
Accounts payable	6,567,000	6,443,000
Accrued expenses	1,446,000	1,986,000
Current portion of operating lease liability	240,000	223,000
Current portion of note payable, net	1,623,000
Total current liabilities	9,876,000	8,652,000
Long-term liabilities:
Operating lease liability	537,000	495,000
Note payable, net	950,000
Total liabilities	11,363,000	9,147,000
Commitments and contingencies (Notes 9, 10 and 14)
Stockholders’ equity:
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 50,251,933 and 49,102,484 as of March 31, 2024 and December 31, 2023, respectively	50,000	49,000
Additional paid-in capital	419,412,000	419,004,000
Accumulated deficit	(415,325,000)	(409,508,000)
Total stockholders’ equity	4,826,000	10,234,000
Total liabilities and stockholders’ equity	16,189,000	19,381,000
Series A Junior Participating Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, Value
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, Value	$ 689,000	$ 689,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.01
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	50,251,933	49,102,484
Common stock, shares outstanding	50,251,933	49,102,484
Series A Junior Participating Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,000,000	250,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	689	689
Preferred stock, shares outstanding	689	689
Preferred stock, stated value	$ 1,000	$ 1,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Clinical treatment programs – US	$ 40	$ 49
Total Revenues	40	49
Costs and Expenses:
Production costs	8
Research and development	1,951	2,052
General and administrative	3,815	2,292
Total Costs and Expenses	5,774	4,344
Operating loss	(5,734)	(4,295)
Gain (Loss) on investments	(92)	203
Interest and other income	81	199
Interest Expense and Other Finance Costs	(72)
(Loss) on sale of assets		(23)
Gain from sale of income tax operating losses		255
Net Loss	$ (5,817)	$ (3,661)
Basic loss per share	$ (0.12)	$ (0.08)
Diluted loss per share	$ (0.12)	$ (0.08)
Weighted average shares outstanding basic	49,458,023	48,399,950
Weighted average shares outstanding diluted	49,458,023	48,399,950

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance ,value at Dec. 31, 2022	$ 696	$ 48	$ 418,270		$ (380,546)	$ 38,468
Balance, shares at Dec. 31, 2022		48,084,287
Common Stock issuance, net of costs			100			100
Common stock issuance, net of costs, shares		322,583
Equity based compensation			82			82
Series B preferred shares converted to common	(4)		4
Series B preferred shares converted to common, shares		456
Net comprehensive loss					(3,661)	(3,661)
Balance ,value at Mar. 31, 2023	692	$ 48	418,456		(384,207)	34,989
Balance, shares at Mar. 31, 2023		48,407,326
Balance ,value at Dec. 31, 2022	696	$ 48	418,270		(380,546)	38,468
Balance, shares at Dec. 31, 2022		48,084,287
Balance ,value at Dec. 31, 2023	689	$ 49	419,004		(409,508)	10,234
Balance, shares at Dec. 31, 2023		49,102,484
Common Stock issuance, net of costs		$ 1	328			329
Common stock issuance, net of costs, shares		807,577
Cashless Exercise of Warrants
Warrants in shares						3,272
Equity based compensation			80			$ 80
Series B preferred shares converted to common
Series B preferred shares converted to common, shares
Committed Shares
Committed Shares (Shares)						338,600
Net comprehensive loss					(5,817)	$ (5,817)
Balance ,value at Mar. 31, 2024	$ 689	$ 50	$ 419,412		$ (415,325)	$ 4,826
Balance, shares at Mar. 31, 2024		50,251,933

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (5,817,000)	$ (3,661,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	9,000	11,000
Amortization of patent, trademark rights	49,000	36,000
Amortization of Debt Discount and Other Expenses	73,000
Non-cash lease expense	(67,000)	37,000
Gain from sale of income tax operating losses		(255,000)
Equity-based compensation	80,000	82,000
Loss (gain) on sale of marketable investments	92,000	(203,000)
Change in assets and liabilities:
Funds receivable from New Jersey net operating loss	1,184,000
Prepaid expenses and other current assets and other non-current assets	(62,000)	(180,000)
Lease liability	60,000	(23,000)
Accounts payable	124,000	586,000
Accrued expenses	(540,000)	(110,000)
Net cash used in operating activities	(4,815,000)	(3,680,000)
Cash flows from investing activities:
Proceeds from sale of marketable investments	50,000	598,000
Purchase of marketable investments	(158,000)	(712,000)
(Purchase) abandonment of patent and trademark rights	(50,000)	7,000
Proceeds from sales of property and equipment		29,000
Net cash used in investing activities	(158,000)	(78,000)
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs	329,000	100,000
Proceeds from note payable, net of issuance costs	2,500,000
Net cash provided by financing activities	2,829,000	100,000
Net decrease in cash and cash equivalents	(2,144,000)	(3,658,000)
Cash and cash equivalents at beginning of period	5,439,000	27,053,000
Cash and cash equivalents at end of period	3,295,000	23,395,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Conversion of Series B preferred		$ 4,000

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection (Interferon alfa). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company’s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Company is currently proceeding primarily in four areas: ● Conducting a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients. ● Evaluating Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors. ● Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. ● Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or Post-COVID conditions of fatigue. The Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (“EMA”), which trials support a potential future NDA. However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues. AIM’s business plan requires one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen and its Active Pharmaceutical Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly C12U polynucleotides, respectively. Additionally, our relationship with Polysciences Inc. (“Polysciences”) continues and R&D development of polymer manufacture is ongoing. In the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2023, and 2022, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 29, 2024. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, equity-based compensation calculations, fair value of warrants, and contingency accruals.

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2024
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 2 Cash and Cash Equivalents Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the three months ended March 31, 2024, some accounts held at financial institutions were in excess of the federally insured limit of $ 250,000

Marketable Investments

Marketable Investments	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Investments	Note 3: Marketable Investments Marketable investments consist of mutual funds. At March 31, 2024 and December 31, 2023, it was determined that none of the marketable investments had an other-than-temporary impairment. At March 31, 2024 and December 31, 2023, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 7: Fair Value). At March 31, 2024, and December 31, 2023 the Company held $ 7,647,000 7,631,000 Mutual Funds classified as available for sale consisted of: Schedule of Available of Sale March 31, 2024 (in thousands) Securities Fair Short-Term Mutual Funds $ 7,647 $ 7,647 Totals $ 7,647 $ 7,647 Schedule of Equity Securities Securities March 31, 2024 Net gains and losses recognized during the period on equity securities $ (92 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (20 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (72 ) Mutual Funds classified as available for sale consisted of: December 31, 2023 (in thousands) Securities Fair Short-Term Mutual Funds $ 7,631 $ 7,631 Totals $ 7,631 $ 7,631 Securities March 31, 2023 Net losses recognized during the period on equity securities $ 290 Less: Net gains and losses recognized during the period on equity securities sold during the period (87 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ 203

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 4: Property and Equipment, net Schedule of Property and Equipment March 31, 2024 December 31, 2023 (in thousands) March 31, 2024 December 31, 2023 Furniture, fixtures, and equipment $ 1,448 $ 1,448 Less: accumulated depreciation (1,330 ) (1,321 ) Property and equipment, net $ 118 $ 127 Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to ten years. Depreciation expense for the three months ending March 31, 2024 and March 31, 2023 was $ 9,000 11,000

Patents and Trademark Rights, N

Patents and Trademark Rights, Net	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and Trademark Rights, Net	Note 5: Patents and Trademark Rights, Net Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights March 31, 2024 December 31, 2023 Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Patents $ 2,995 $ (794 ) $ 2,201 $ 2,947 $ (750 ) $ 2,197 Trademarks 231 (118 ) 113 229 (113 ) 116 Net amortizable patents and trademarks rights $ 3,226 $ (912 ) $ 2,314 $ 3,176 $ (863 ) $ 2,313 Schedule of Changes in Patents, Trademark Rights December 31, 2023 $ 2,313 Acquisitions 50 Abandonments — Amortization (49 ) March 31, 2024 $ 2,314 Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life of 17 10 12 7 Amortization of patents and trademarks for each of the next five years and thereafter is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2024 $ 186 2025 237 2026 235 2027 212 2028 193 Thereafter 1,251 Total $ 2,314

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases
Leases	Note 6: Leases The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 5 1,000 17,000 1 5 At March 31, 2024 and December 31, 2023, the balance of the right of use assets was $ 763,000 697,000 777,000 718,000 296,000 363,000 AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease March 31, 2024 December 31, 2023 (in thousands) March 31, 2024 March 31, 2023 Lease costs: Operating lease costs $ 74 $ 68 Short-term and variable lease costs 49 19 Total lease costs $ 123 $ 87 Classification of lease costs Research & development $ 101 $ 19 General and administrative 22 68 Lease cost 22 68 Total lease costs $ 123 $ 87 The Company’s leases have remaining lease terms between 11 and 40 months. As of March 31, 2024, the weighted-average remaining term was 39 months. At December 31, 2023, the weighted-average remaining term was 41 months. The Company’s weighted average incremental borrowing rate for its leases was 10 % at March 31, 2024 and December 31, 2023. Future minimum payments as of March 31, 2024, are as follows: Schedule of Operating Lease Future Payments Year Ending December 31, (in thousands) 2024 $ 229 2025 273 2026 244 2027 159 Thereafter — Less imputed interest (128 ) Total $ 777

Fair Value

Fair Value	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 7: Fair Value Fair Value The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: 1. Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market. 2. Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. 3. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of March 31, 2024, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of March 31, 2024 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 1,478 $ 1,478 $ — $ — Marketable investments $ 7,647 $ 7,647 $ — $ — As of December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 4,805 $ 4,805 $ — $ — Marketable investments $ 7,631 $ 7,631 $ — $ — The Company’s cash balances are representative of their fair values as these balances are comprised of deposits available on demand. For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1). The Company also had certain redeemable warrants in the Rights Offering with a cash settlement feature in the occurrence of a Fundamental Transaction. No Fundamental Transaction occurred. During the first quarter 2024, 205,000 of these Warrants converted on a cashless basis and the balance expired.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses	Note 8: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses March 31, 2024 December 31, 2023 (in thousands) March 31, 2024 December 31, 2023 Compensation $ 451 $ 414 Professional fees 881 1,352 Clinical trial expenses 103 184 Other expenses 11 36 Total $ 1,446 $ 1,986

Unsecured Promissory Note

Unsecured Promissory Note	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Unsecured Promissory Note	Note 9: Unsecured Promissory Note On February 16, 2024, the Company (“Borrower”) entered into a Note Purchase Agreement with Streeterville Capital LLC (“Streeterville”or the “Lender”). Under the terms of the agreement, Streeterville paid the Company $ 2,500,000 781,250 3,301,250 20,000 10 The following table summarizes our debt at March 31, 2024 and December 31, 2023: (in thousands) Schedule of Long Term Debt March 31, 2024 December 31, 2023 Long-term debt $ 3,330 $ - Unamortized Original issue discount (738 ) - Unamortized Financing fees (19 ) - Unamortized discount and debt issuance costs 2,573 - Less current portion of long-term debt, net (1) (1,623 ) - Long-term debt (2) $ 950 $ - Interest costs expensed and capitalized related to long-term debt were as follows: (in thousands) Schedule of Long Term Debt Interest Costs Expense and Capital March 31, 2024 December 31, 2023 Interest expense $ 29 $ - Interest capitalized - - Total $ 29 $ - Amortization expenses related to long-term debt were as follows: (in thousands) Schedule of Long Term Debt Amortization Expenses March 31, 2024 December 31, 2023 Original issue discount $ 43 $ - Loan fee amortization 1 - Total $ 44 $ - Future maturities of long-term debt as of March 31, 2024 were as follows: (in thousands) Schedule of Future Maturities of Long Term Debt Fiscal years ending December 31: 2024 $ 1,250 2025 2,080 Total $ 3,330 (1) Current portion of long-term debt of approximately $ 2,000,000 367,000 10,000 as of March 31, 2024. (2) Long-term portion of debt of approximately $ 1,330,000 371,000 9,000 The agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.

Equity Purchase Agreement

Equity Purchase Agreement	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Equity Purchase Agreement	Note 10: Equity Purchase Agreement On March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement (collectively, the “Atlas Agreements”) with Atlas Sciences, LLC (“Atlas”), pursuant to which Atlas committed to purchase up to $ 15,000,000 Under the terms of the agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor at 95% of the Market Price of the shares on the day of trade. Sales under the agreement are limited to a daily maximum of the lessor of: $ 500,000 4.99 19.99 9,975,000 9,636,400 338,600

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Equity	Note 11: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 4,000,000 10,000 Series A Junior Participating Preferred Stock On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to 4,000,000 250,000 Series B Convertible Preferred Stock The Company has designated 10,000 0.01 1,000 Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $ 0.20 Pursuant to a registration statement relating to a rights offering (the “Rights Offering”) declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 4,700,000 no At March 31, 2024 and December 31, 2023, the Company had 689 114 689 (b) Common Stock and Equity Finances The Company has authorized shares of 350,000,000 8,000,000 350,000,000 50,251,933 49,102,484 Employee Stock Purchase Plan (Not equity compensation) On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 During the three months ended March 31, 2024, the Company issued a total of 243,009 0.33 0.39 82,500 During the three months ended March 31, 2023, the Company issued a total of 322,583 shares of its Common Stock at a price of $ 0.31 for total proceeds of approximately $ 100,000 as part of the employee stock purchase plan. Warrants (Rights offering) On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 266,665 0.90 0.99 0.899 4.99 0.001 7,200,000 1,870,000 8,873,960 266,665 264,000 46,000 205,000 5,830,028 15,000 152,160 Equity Distribution Agreement On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 8,500 000 through Maxim, as agent (the “Offering”). Sales under the EDA were registered under the S-3 Shelf Registration Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of 3.0 % of the gross sales price of shares sold under the EDA. For the three months ended March 31, 2024, the Company sold 564,568 shares under the EDA for total gross proceeds of approximately $ 253,870 , which includes a 3.0 % fee to Maxim of $ 7,616 . During the year ended December 31, 2023, the Company sold 598,114 shares under the EDA for total gross proceeds of approximately $ 344,000 , which includes a 3.0% fee to Maxim of $ 10,326 . Subsequent to March 31, 2024, the Company sold 730,110 shares under the EDA for total gross proceeds of $ 372,223 , which includes a 3.0 % fee to Maxim of $ 11,167 Rights Plan On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”).

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 12: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 3,386,789 2,522,390

Equity-Based Compensation

Equity-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 13: Equity-Based Compensation The 2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the “2018 Equity Incentive Plan”) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 250,000 979,311 956,660 960,976 968,389 10,865,336 10 1,189,284 9.68 10 1,727,756 9.68 ten years 1,025,000 2.77 3.07 ten years 613,512 1.11 1.71 ten years 850,000 0.31 0.71 ten years 400,000 0.47 ten years no The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. During the three months ended March 31, 2023 and 2024, there were no Stock options activity during the three months ended March 31, 2024, was as follows: Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2024 2,408,438 $ 2.50 8.70 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2024 2,408,438 $ 2.50 8.70 $ — Vested and expected to vest March 31, 2024 2,141,772 $ 1.83 6.89 $ — Exercisable March 31, 2024 2,141,772 $ 1.83 6.89 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2024 366,666 $ 2.13 12.44 $ — Granted — — — — Expired — — — — Vested (100,000 ) 0.47 6.89 — Unvested March 31, 2024 266,666 $ 2.75 14.52 $ — Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2024 885,055 $ 2.02 9.23 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2024 885,055 $ 2.02 9.23 $ — Vested and expected to vest March 31, 2024 640,055 $ 2.27 10.04 $ — Exercisable March 31, 2024 640,055 $ 2.27 10.04 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2024 335,001 $ 1.83 10.70 $ — Granted — — — — Expired — — — — Vested (90,000 ) 0.46 9.47 — Unvested March 31, 2024 245,001 $ 2.33 11.15 $ — Stock-based compensation expense was approximately $ 80,000 82,000 As of March 31, 2024, and 2023, respectively, there was approximately $ 214,000 134,000

Research, Consulting and Supply

Research, Consulting and Supply Agreements	3 Months Ended
	Mar. 31, 2024
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 14: Research, Consulting and Supply Agreements The Company has entered into research, consulting and supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred. During the three months ended March 31, 2024, research and development expenses were comprised of: clinical studies ($ 948,000 246,000 550,000 207,000 The following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related to research and development costs for the three months ended March 31, 2024. Amarex Clinical Research LLC Amarex is the principal administrator of several of AIM’s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the three months ended March 31, 2024 and 2023, the Company incurred approximately $ 521,000 455,000 ● Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $ 8,400,000 1,000,000 4.6 ○ During the three months ended March 31, 2024, the Company incurred approximately $ 86,000 ○ During the three months ended March 31, 2023, the Company incurred approximately $ 174,000 ● Post-COVID Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $ 6,400,000 125,000 4,400,000 6,600,000 ○ During the three months ended March 31, 2024, the Company incurred approximately $ 435,000 ○ During the three months ended March 31, 2023, the Company incurred approximately $ 281,000 Jubilant HollisterStier Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, two lots of Ampligen consisting of more than 16,000 27,900 1,432,000 ○ During the three months ended March 31, 2024, the Company incurred approximately $ 1,000 ○ During the three months ended March 31, 2023, the Company did not incur any expense related to this agreement. Sterling Pharma Solutions In 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. ○ During the three months ended March 31, 2024, the Company incurred approximately $ 129,000 ○ During the three months ended March 31, 2023, the Company incurred approximately $ 357,000 Erasmus In December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM’s limited responsibilities are limited to providing Ampligen. Additionally, in April 2023 AIM agreed to provide to Erasmus MC an unrestricted grant of $ 200,000 ○ During the three months ended March 31, 2024, the Company incurred approximately $ 4,000 ○ During the three months ended March 31, 2023, the Company did not incur any expense related to this agreement. Azenova Sales International In October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services for AIM’s Ampligen product for solid tumors for a 12 month term that is extendable upon the agreement of the parties. In exchange for its services, Azenova will receive a fixed monthly retainer of $ 30,000 360,000 ○ During the three months ended March 31, 2024, the Company incurred approximately $ 90,000 ○ During the three months ended March 31, 2023, the Company did not incur any expense related to this agreement. Alcami In September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging component. The agreement called for fixed costs of approximately $ 30,000 ○ During the three months ended March 31, 2024, the Company incurred approximately $ 10,000 ○ During the three months ended March 31, 2023, the Company incurred approximately $ 8,000

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2024
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 15: Recent Accounting Pronouncements During the first quarter of 2024 accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 16: Subsequent Events In April 2024, the Company filed a registration statement with the SEC on Form S-1 registering a total of 9,975,000 9,636,400 338,600 206,800 In April and May of 2024, the Company sold 730,110 372,223 3.0% 11,167 In April 2024, 689 Deferred 2023 bonuses of $ 500,000 350,000 150,000

Marketable Investments (Tables)

Marketable Investments (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Available of Sale	Mutual Funds classified as available for sale consisted of: Schedule of Available of Sale March 31, 2024 (in thousands) Securities Fair Short-Term Mutual Funds $ 7,647 $ 7,647 Totals $ 7,647 $ 7,647 December 31, 2023 (in thousands) Securities Fair Short-Term Mutual Funds $ 7,631 $ 7,631 Totals $ 7,631 $ 7,631
Schedule of Equity Securities	Schedule of Equity Securities Securities March 31, 2024 Net gains and losses recognized during the period on equity securities $ (92 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (20 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (72 ) Securities March 31, 2023 Net losses recognized during the period on equity securities $ 290 Less: Net gains and losses recognized during the period on equity securities sold during the period (87 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ 203

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment March 31, 2024 December 31, 2023 (in thousands) March 31, 2024 December 31, 2023 Furniture, fixtures, and equipment $ 1,448 $ 1,448 Less: accumulated depreciation (1,330 ) (1,321 ) Property and equipment, net $ 118 $ 127

Patents and Trademark Rights,_2

Patents and Trademark Rights, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patent and Trademark Rights	Patent and trademark rights consist of the following (in thousands): Schedule of Patent and Trademark Rights March 31, 2024 December 31, 2023 Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Patents $ 2,995 $ (794 ) $ 2,201 $ 2,947 $ (750 ) $ 2,197 Trademarks 231 (118 ) 113 229 (113 ) 116 Net amortizable patents and trademarks rights $ 3,226 $ (912 ) $ 2,314 $ 3,176 $ (863 ) $ 2,313
Schedule of Changes in Patents, Trademark Rights	Schedule of Changes in Patents, Trademark Rights December 31, 2023 $ 2,313 Acquisitions 50 Abandonments — Amortization (49 ) March 31, 2024 $ 2,314
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years and thereafter is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2024 $ 186 2025 237 2026 235 2027 212 2028 193 Thereafter 1,251 Total $ 2,314

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases
Schedule of AIM Recognized Rent Expense Associated with Operating Lease	AIM recognized rent expense associated with these leases are follows: Schedule of AIM Recognized Rent Expense Associated with Operating Lease March 31, 2024 December 31, 2023 (in thousands) March 31, 2024 March 31, 2023 Lease costs: Operating lease costs $ 74 $ 68 Short-term and variable lease costs 49 19 Total lease costs $ 123 $ 87 Classification of lease costs Research & development $ 101 $ 19 General and administrative 22 68 Lease cost 22 68 Total lease costs $ 123 $ 87
Schedule of Operating Lease Future Payments	Future minimum payments as of March 31, 2024, are as follows: Schedule of Operating Lease Future Payments Year Ending December 31, (in thousands) 2024 $ 229 2025 273 2026 244 2027 159 Thereafter — Less imputed interest (128 ) Total $ 777

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of March 31, 2024 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 1,478 $ 1,478 $ — $ — Marketable investments $ 7,647 $ 7,647 $ — $ — As of December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 4,805 $ 4,805 $ — $ — Marketable investments $ 7,631 $ 7,631 $ — $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses March 31, 2024 December 31, 2023 (in thousands) March 31, 2024 December 31, 2023 Compensation $ 451 $ 414 Professional fees 881 1,352 Clinical trial expenses 103 184 Other expenses 11 36 Total $ 1,446 $ 1,986

Unsecured Promissory Note (Tabl

Unsecured Promissory Note (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long Term Debt	The following table summarizes our debt at March 31, 2024 and December 31, 2023: (in thousands) Schedule of Long Term Debt March 31, 2024 December 31, 2023 Long-term debt $ 3,330 $ - Unamortized Original issue discount (738 ) - Unamortized Financing fees (19 ) - Unamortized discount and debt issuance costs 2,573 - Less current portion of long-term debt, net (1) (1,623 ) - Long-term debt (2) $ 950 $ - (1) Current portion of long-term debt of approximately $ 2,000,000 367,000 10,000 as of March 31, 2024. (2) Long-term portion of debt of approximately $ 1,330,000 371,000 9,000
Schedule of Long Term Debt Interest Costs Expense and Capital	Interest costs expensed and capitalized related to long-term debt were as follows: (in thousands) Schedule of Long Term Debt Interest Costs Expense and Capital March 31, 2024 December 31, 2023 Interest expense $ 29 $ - Interest capitalized - - Total $ 29 $ -
Schedule of Long Term Debt Amortization Expenses	Amortization expenses related to long-term debt were as follows: (in thousands) Schedule of Long Term Debt Amortization Expenses March 31, 2024 December 31, 2023 Original issue discount $ 43 $ - Loan fee amortization 1 - Total $ 44 $ -
Schedule of Future Maturities of Long Term Debt	Future maturities of long-term debt as of March 31, 2024 were as follows: (in thousands) Schedule of Future Maturities of Long Term Debt Fiscal years ending December 31: 2024 $ 1,250 2025 2,080 Total $ 3,330

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2024 2,408,438 $ 2.50 8.70 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2024 2,408,438 $ 2.50 8.70 $ — Vested and expected to vest March 31, 2024 2,141,772 $ 1.83 6.89 $ — Exercisable March 31, 2024 2,141,772 $ 1.83 6.89 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2024 366,666 $ 2.13 12.44 $ — Granted — — — — Expired — — — — Vested (100,000 ) 0.47 6.89 — Unvested March 31, 2024 266,666 $ 2.75 14.52 $ —
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2024 885,055 $ 2.02 9.23 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2024 885,055 $ 2.02 9.23 $ — Vested and expected to vest March 31, 2024 640,055 $ 2.27 10.04 $ — Exercisable March 31, 2024 640,055 $ 2.27 10.04 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2024 335,001 $ 1.83 10.70 $ — Granted — — — — Expired — — — — Vested (90,000 ) 0.46 9.47 — Unvested March 31, 2024 245,001 $ 2.33 11.15 $ —

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details Narrative)	Mar. 31, 2024 USD ($)
Cash and Cash Equivalents [Abstract]
Federlly insured limit	$ 250,000

Schedule of Available of Sale (

Schedule of Available of Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Marketable Securities [Line Items]
Fair Value	$ 7,647	$ 7,631
Short-Term Investments	7,647	7,631
Mutual Funds [Member]
Marketable Securities [Line Items]
Fair Value	7,647	7,631
Short-Term Investments	$ 7,647	$ 7,631

Schedule of Equity Securities (

Schedule of Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Net gain recognized during the period on equity securities	$ (92)	$ 290
Net gains and losses recognized during the period on equity securities sold during the period	(20)	(87)
Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date	$ (72)	$ 203

Marketable Investments (Details

Marketable Investments (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Marketable Securities [Line Items]
Held value of marketable securities	$ 7,647,000		$ 7,631,000
Fair Value	7,647,000		7,631,000
Short-Term Investments	7,647,000		7,631,000
Net gain recognized during the period on equity securities	(92,000)	$ 290,000
Net gains and losses recognized during the period on equity securities sold during the period	(20,000)	(87,000)
Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date	(72,000)	$ 203,000
Mutual Funds [Member]
Marketable Securities [Line Items]
Fair Value	7,647,000		7,631,000
Short-Term Investments	$ 7,647,000		$ 7,631,000

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Furniture, fixtures, and equipment	$ 1,448	$ 1,448
Less: accumulated depreciation	(1,330)	(1,321)
Property and equipment, net	$ 118	$ 127

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 9,000	$ 11,000

Schedule of Patent and Trademar

Schedule of Patent and Trademark Rights (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 3,226	$ 3,176
Accumulated amortization	(912)	(863)
Net carrying value	2,314	2,313
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	2,995	2,947
Accumulated amortization	(794)	(750)
Net carrying value	2,201	2,197
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	231	229
Accumulated amortization	(118)	(113)
Net carrying value	$ 113	$ 116

Schedule of Changes in Patents,

Schedule of Changes in Patents, Trademark Rights (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 2,313
Acquisitions	50
Abandonments
Accumulated Amortization	(49)	$ (36)
Ending balance	$ 2,314

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 186
2025	237
2026	235
2027	212
2028	193
Thereafter	1,251
Total	$ 2,314	$ 2,313

Patents and Trademark Rights,_3

Patents and Trademark Rights, Net (Details Narrative)	3 Months Ended
	Mar. 31, 2024
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, estimated useful life	17 years
Finite lived intangible assets, weighted average amortization	12 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, estimated useful life	10 years
Finite lived intangible assets, weighted average amortization	7 years

Schedule of AIM Recognized Rent

Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Lease costs:
Lease cost	$ 74	$ 68
Short-term and variable lease costs	49	19
Total lease costs	123	87
Research and Development Expense [Member]
Lease costs:
Lease cost	101	19
General and Administrative Expense [Member]
Lease costs:
Lease cost	$ 22	$ 68

Schedule of Operating Lease Fut

Schedule of Operating Lease Future Payments (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Leases
2024	$ 229,000
2025	273,000
2026	244,000
2027	159,000
Thereafter
Less imputed interest	(128,000)
Total	$ 777,000	$ 718,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Right of use asset	$ 763,000	$ 697,000
Lease liability	777,000	718,000
Accumulated amortization	$ 296,000	$ 363,000
Lessee, Operating Lease, Remaining Lease Term		41 months
Operating Lease, Weighted Average Remaining Lease Term	39 months
Debt, Weighted Average Interest Rate	10%	10%
Minimum [Member]
Operating lease term	1 year
Operating lease Payment	$ 1,000
Lessee, Operating Lease, Remaining Lease Term	11 months
Maximum [Member]
Operating lease term	5 years
Operating lease Payment	$ 17,000
Lessee, Operating Lease, Remaining Lease Term	40 months

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments	$ 1,478	$ 4,805
Marketable securities	7,647	7,631
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments	1,478	4,805
Marketable securities	7,647	7,631
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments
Marketable securities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents-Marketable investments
Marketable securities

Fair Value (Details Narrative)

Fair Value (Details Narrative)	Mar. 31, 2024 shares
Fair Value Disclosures [Abstract]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	205,000

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Compensation	$ 451	$ 414
Professional fees	881	1,352
Clinical trial expenses	103	184
Other expenses	11	36
Total	$ 1,446	$ 1,986

Schedule of Long Term Debt (Det

Schedule of Long Term Debt (Details) - USD ($) $ in Thousands		Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-term debt		$ 3,330
Unamortized Original issue discount		(738)
Unamortized Financing fees		(19)
Unamortized discount and debt issuance costs		2,573
Less current portion of long-term debt, net	[1]	(1,623)
Long-term debt	[2]	$ 950
[1]Current portion of long-term debt of approximately $ 2,000,000 367,000 1,330,000 371,000 9,000

Schedule of Long Term Debt Inte

Schedule of Long Term Debt Interest Costs Expense and Capital (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Interest expense	$ 29
Interest capitalized
Total	$ 29

Schedule of Long Term Debt Amor

Schedule of Long Term Debt Amortization Expenses (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Original issue discount	$ 43
Loan fee amortization	1
Total	$ 44

Schedule of Future Maturities o

Schedule of Future Maturities of Long Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
2024	$ 1,250
2025	2,080
Total	$ 3,330

Schedule of Long Term Debt (D_2

Schedule of Long Term Debt (Details) (Parenthetical) $ in Thousands	Mar. 31, 2024 USD ($)
Debt Disclosure [Abstract]
Long-term debt, current	$ 2,000,000
Debt discount, current	367,000
Debt origination costs, current	10,000
Long-term debt, non current	1,330,000
Debt discount, non current	371,000
Debt origination costs, non current	$ 9,000

Unsecured Promissory Note (Deta

Unsecured Promissory Note (Details Narrative) - USD ($)	Feb. 16, 2024	Mar. 31, 2024	Dec. 31, 2023
Line of Credit Facility [Line Items]
Long term debt		$ 3,330,000
Note Purchase Agreement [Member] | Streeterville Capital LLC [Member]
Line of Credit Facility [Line Items]
Exchange of unsecured promissory notes	$ 2,500,000
Unsecured debt original issue discount	781,250
Long term debt	3,301,250
Debt issuance costs	$ 20,000
Debt instrument stated interest rate	10%
Redemption description	The agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.

Equity Purchase Agreement (Deta

Equity Purchase Agreement (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	Mar. 28, 2024	Apr. 30, 2024	Mar. 31, 2024	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock			$ 329,000	$ 100,000
Purchase And Registration Rights Agreement [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock sold by the company		9,975,000
Purchase And Registration Rights Agreement [Member] | Atlas Sciences LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity investment ownership percentage	19.99%
Atlas Sciences LLC [Member] | Purchase And Registration Rights Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Trading maximum lessor amount	$ 500,000
Beneficial ownership percentage	4.99%
Atlas Sciences LLC [Member] | Purchase And Registration Rights Agreement [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock sold by the company		9,636,400
Commitment shares issued		$ 338,600
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock			$ 1,000
Common Stock [Member] | Atlas Sciences LLC [Member] | Purchase And Registration Rights Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock	$ 15,000,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 19, 2023	Jul. 07, 2020	Mar. 31, 2020	Sep. 27, 2019	Apr. 30, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2020	May 10, 2023	May 09, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized						5,000,000
Preferred stock, par value						$ 0.01
Preferred stock conversion price						0.20
Exercise price						$ 8.80
Warrants issued						114
Net proceeds from warrants
Common stock, shares authorized						350,000,000		350,000,000
Common stock specific limitations and restrictions on usage						8,000,000
Common stock, shares outstanding						50,251,933		49,102,484
Common stock shares issued, value						$ 329,000	$ 100,000
Warrants exercised aggregate						205,000
Proceeds from Issuance or Sale of Equity						$ 329,000	100,000
Warrant gross proceeds			$ 264,000
Warrant modification			$ 46,000
Warrant outstanding						15,000		152,160
Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants issued				7,148,310
Number of shares issued upon transaction				1,740,550
Proceeds from Issuance or Sale of Equity				$ 7,200,000
Maxim Group LLC [Member] | Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Common stock shares issued, value	$ 8,500
Number of shares issued upon transaction						564,568		598,114
Proceeds from issuance of common stock					$ 372,223	$ 253,870		$ 344,000
Sale of Stock, Percentage of Ownership after Transaction	3%				3%	3%		3%
Sale of Stock, Consideration Received on Transaction					$ 11,167	$ 7,616		$ 10,326
Maxim Group LLC [Member] | Equity Distribution Agreement [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction					730,110
Proceeds from issuance of common stock					$ 372,223
Sale of Stock, Percentage of Ownership after Transaction					3%
Sale of Stock, Consideration Received on Transaction					$ 11,167
Directors, Officers and Employees [Member]
Class of Stock [Line Items]
Common stock shares issued, value		$ 500,000
Common Stock [Member]
Class of Stock [Line Items]
Exercise price						$ 8.80
Net proceeds from warrants
Common stock shares issued, value						$ 1,000
Number of shares issued upon transaction						807,577	322,583
Warrants [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants exercised aggregate				8,888,860
Representative Warrants [Member] | Maximum [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Warrants exercised aggregate			266,665	266,665		5,830,028
Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Exercise price				$ 0.001
Shares issued price per share				$ 0.899
Percentage of outstanding stock				4.99%
Pre-funded warrants exercised									1,870,000
Pre-Funded Warrants [Member] | Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Shares issued price per share				$ 0.90
Warrant [Member]
Class of Stock [Line Items]
Exercise price				$ 0.99
Pre-funded warrants exercised						205,000			8,873,960
Rights [Member]
Class of Stock [Line Items]
Subscription price						$ 1,000
Convertible preferred stock face value						1,000
Net proceeds from warrants						$ 4,700,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized						4,000,000		250,000		250,000	4,000,000
Preferred stock, par value						$ 0.001		$ 0.001
Preferred stock, shares outstanding
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized						10,000		10,000
Preferred stock, par value						$ 0.01
Preferred stock, stated value						$ 1,000		$ 1,000
Conversion of shares issued						0
Preferred stock, shares outstanding						689		689
Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares to be issued on conversion						114
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction						243,009
Proceeds from issuance of common stock						$ 82,500
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Shares issued price per share						$ 0.33
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Shares issued price per share						$ 0.39
Common Stock One [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction							322,583
Shares issued price per share							$ 0.31
Proceeds from issuance of common stock							$ 100,000

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	3,386,789	2,522,390

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period | shares	2,408,438
Weighted Average Exercise Price Outstanding, Beginning of Period | $ / shares	$ 2.50
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 8 months 12 days
Aggregate Intrinsic Value Outstanding, Beginning of Period | $
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Aggregate Intrinsic Value, Forfeited | $
Number of Options, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Aggregate Intrinsic Value, Expired | $
Number of Options Outstanding, Ending of Period | shares	2,408,438
Weighted Average Exercise Price Outstanding, End of Period | $ / shares	$ 2.50
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 8 months 12 days
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Vested and Expected to Vest | shares	2,141,772
Weighted Average Exercise Price, Vested and Expected to Vest | $ / shares	$ 1.83
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	6 years 10 months 20 days
Aggregate Intrinsic Value, Vested and Expected to Vest | $
Number of Options Exercisable, End of Period | shares	2,141,772
Weighted Average Exercise Price Exercisable, Ending of Period | $ / shares	$ 1.83
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	6 years 10 months 20 days
Aggregate Intrinsic Value, Exercisable at End of Period | $
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period | shares	885,055
Weighted Average Exercise Price Outstanding, Beginning of Period | $ / shares	$ 2.02
Weighted Average Remaining Contracted Term (years) Outstanding	9 years 2 months 23 days
Aggregate Intrinsic Value Outstanding, Beginning of Period | $
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Options, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Aggregate Intrinsic Value, Forfeited | $
Number of Options, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Number of Options Outstanding, Ending of Period | shares	885,055
Weighted Average Exercise Price Outstanding, End of Period | $ / shares	$ 2.02
Weighted Average Remaining Contracted Term (years) Outstanding	9 years 2 months 23 days
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Vested and Expected to Vest | shares	640,055
Weighted Average Exercise Price, Vested and Expected to Vest | $ / shares	$ 2.27
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	10 years 14 days
Aggregate Intrinsic Value, Vested and Expected to Vest | $
Number of Options Exercisable, End of Period | shares	640,055
Weighted Average Exercise Price Exercisable, Ending of Period | $ / shares	$ 2.27
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	10 years 14 days
Aggregate Intrinsic Value, Expired | $

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Granted	0	0
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	366,666
Weighted Average Exercise Price Unvested, Beginning of Period	$ 2.13
Average Remaining Contractual Term (years) Unvested, Beginning of Period	12 years 5 months 8 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(100,000)
Weighted Average Exercise Price, Vested	$ 0.47
Average Remaining Contractual Term Vested	6 years 10 months 20 days
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	266,666
Weighted Average Exercise Price Unvested, Ending of Period	$ 2.75
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	14 years 6 months 7 days
Aggregate Intrinsic Value Unvested, End of Period
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	335,001
Weighted Average Exercise Price Unvested, Beginning of Period	$ 1.83
Average Remaining Contractual Term (years) Unvested, Beginning of Period	10 years 8 months 12 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(90,000)
Weighted Average Exercise Price, Vested	$ 0.46
Average Remaining Contractual Term Vested	9 years 5 months 19 days
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	245,001
Weighted Average Exercise Price Unvested, Ending of Period	$ 2.33
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	11 years 1 month 24 days
Aggregate Intrinsic Value Unvested, End of Period

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($)

3 Months Ended

12 Months Ended

Sep. 12, 2018

Mar. 31, 2024

Mar. 31, 2023

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Jan. 01, 2024

Jul. 01, 2023

Jul. 01, 2022

Jul. 01, 2021

Aug. 03, 2020

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

0

0

Share based compensation expense

$ 80,000

$ 82,000

Unrecognized equity based compensation

$ 214,000

$ 134,000

2018 Equity Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of stock is reserved for potential issuance

7,000,000

10,865,336

968,389

960,976

956,660

979,311

Option vested years

10 years

2018 Equity Incentive Plan [Member] | Officer [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Option vested years

10 years

Options, granted

400,000

850,000

613,512

1,025,000

1,727,756

1,189,284

Exercise price range

$ 0.47

$ 9.68

$ 9.68

Expiration period

10 years

10 years

10 years

10 years

2018 Equity Incentive Plan [Member] | Officer [Member] | Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options, granted

0.31

Exercise price range

$ 1.11

$ 2.77

2018 Equity Incentive Plan [Member] | Officer [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Exercise price range

$ 0.71

$ 1.71

$ 3.07

Restated 2018 Equity Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of stock is reserved for potential issuance

250,000

Research, Consulting and Supp_2

Research, Consulting and Supply Agreements (Details Narrative)	1 Months Ended				3 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Apr. 30, 2022 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($) Integer	Dec. 31, 2023 USD ($)	Dec. 31, 2017 Integer	Oct. 31, 2023 USD ($) shares
Research and development expense					$ 1,951,000	$ 2,052,000
Amarex Clinical Research LLC [Member]
Research and development expense					521,000	455,000
Research and development expense excluding acquired in process cost			$ 6,400,000	$ 8,400,000
Development cost			125,000	$ 1,000,000			$ 6,600,000
Estimated lives				4 years 7 months 6 days
Invigilators cost			$ 4,400,000
Amarex Clinical Research LLC [Member] | Advanced Pancreatic Cancer Study Agreement [Member]
Research and development expense					86,000	174,000
Amarex Clinical Research LLC [Member] | Post COVID Study Agreement [Member]
Research and development expense					435,000	$ 281,000
Jubilant HollisterStier [Member]
Number of units manufactured | Integer								16,000
Additional number of vials | Integer						27,900
Inventory work in process and raw materials						$ 1,432,000
Jubilant HollisterStier [Member] | Ampligen Manufacturing Agreement [Member]
Research and development expense					1,000
Sterling Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]
Research and development expense					129,000	357,000
Erasmus University Medical Center [Member] | Joint Clinical Study Agreement [Member]
Research and development expense		$ 200,000			4,000
Azenova LLC [Member] | Consulting Agreement [Member]
Research and development expense					90,000
Stock options, aggregate intrinsic value									$ 30,000
Stock options, vested | shares									360,000
Alcami Corporation [Member]
Research and development expense	$ 30,000				10,000	$ 8,000
Clinical Studies [Member]
Research and development expense					948,000
Manufacturing and Engineering [Member]
Research and development expense					246,000
Quality Control [Member]
Research and development expense					550,000
Regulatory [Member]
Research and development expense					$ 207,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 19, 2023	May 31, 2024	Apr. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Subsequent Event [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Bonus paid		$ 500,000
Subsequent Event [Member] | Deferred Bonus [Member] | Thomas Equels [Member]
Subsequent Event [Line Items]
Bonus paid		350,000
Subsequent Event [Member] | Deferred Bonus [Member] | Peter Rodino [Member]
Subsequent Event [Line Items]
Bonus paid		$ 150,000
Subsequent Event [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares expried			689
Purchase And Registration Rights Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares sold			9,975,000
Purchase And Registration Rights Agreement [Member] | Subsequent Event [Member] | Atlas Sciences LLC [Member]
Subsequent Event [Line Items]
Number of shares sold			9,636,400
Commitment shares issued			$ 338,600
Equity Purchase Agreement [Member] | Subsequent Event [Member] | Atlas Sciences LLC [Member]
Subsequent Event [Line Items]
Number of shares purchased		206,800
Equity Distribution Agreement [Member] | Maxim Group LLC [Member]
Subsequent Event [Line Items]
Number of shares sold			730,110
Number of shares purchased				564,568	598,114
Proceeds from issuance of common stock			$ 372,223	$ 253,870	$ 344,000
Transaction fee rate	3%		3%	3%	3%
Sale of stock, consideration received			$ 11,167	$ 7,616	$ 10,326
Equity Distribution Agreement [Member] | Subsequent Event [Member] | Maxim Group LLC [Member]
Subsequent Event [Line Items]
Number of shares purchased			730,110
Proceeds from issuance of common stock			$ 372,223
Transaction fee rate			3%
Sale of stock, consideration received			$ 11,167